Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani
Orapuh Journal · 09.03.2026 · 6 (10) · e1293
DOI: 10.4314/orapj.v6i10.93 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orapuh Journal, online erschienen am 09.03.2026. Verfasst von Ngwato und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Azithromycin is an antibiotic belonging to the macrolide family. It is widely used in the management of infectious diseases caused by both Gram-positive and Gram-negative bacteria, as well as certain aerobic infections. During the COVID-19 outbreak, its use increased in many countries as part of disease management protocols. Unfortunately, this surge was associated with the introduction of counterfeit products on the market. This drug remains widely circulated, particularly in the far north of Kisangani Province in the Democratic Republic of the Congo.
Purpose
This study aimed to evaluate the quality of marketed Azithromycin tablets available in the region of Kisangani, Democratic Republic of the Congo.
Methods
To achieve this goal, appropriate physicochemical analyses were conducted to verify product quality through organoleptic, pharmaco-technical, qualitative, and quantitative assessments. A total of 14 samples from seven different laboratories (two batches from each) were collected. The study adopted a cross-sectional laboratory-based design using UV-Vis spectrophotometry and HPLC techniques. Data were statistically analysed using the Student’s t-test method.
Results
Analyses yielded satisfactory results for 100% of the samples, which were consistent with survey findings and confirmed the effectiveness and reliability of Azithromycin-based treatment, except for one sample (Zithromcin, batches 1 and 2) that failed the friability test. This non-conforming result represented less than 20% of the total sample size.
Conclusion
The study results align with those obtained from the survey. We recommend that regulatory authorities use similar analytical tests and trials for drug approval processes and the classification of high-monitoring drugs. The analytical methods implemented in this research can serve as reference procedures for routine quality control of this macrolide antibiotic.
Zitieren
APA
Ngwato, W., J., Mankulu, J., K., Mayangi, M., M., Ntambwe, M., Koy-Sita, M., P., J., Liesse, M., I. J., Ciza, & P., H. (2026). Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani. Orapuh Journal, 6(10), e1293. https://doi.org/10.4314/orapj.v6i10.93
Vancouver
Ngwato, W. J, Mankulu, J. K, Mayangi, M. M, et al. Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani. Orapuh Journal. 2026;6(10):e1293. doi:10.4314/orapj.v6i10.93
BibTeX
@article{Ngwato2026,
author = {Ngwato and W., J. and Mankulu and J., K. and Mayangi and M., M. and Ntambwe and M. and Koy-Sita, Mufusama and P., J. and Liesse and M., I. J. and Ciza and P., H.},
title = {Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani},
journal = {Orapuh Journal},
year = {2026},
volume = {6},
number = {10},
pages = {e1293},
doi = {10.4314/orapj.v6i10.93}
}
EUVIMED